MOHS

MOHS acquires major pharma company

In pursuit of its strategy of vertical integration of its flagship healthcare and wellness business, MOHS Analytics has acquired majority ownership of Remed Pharmaceuticals, Inc., a research and development-driven company founded in 2002 by pharmaceutical industry pillar Remedios A. Rivera.

MOHS

Standing from Left to Right: Dr. Kenji M. Asano Jr.(MOHS SVP & Group CFO), Remedios A. Rivera, (Remed Chairman and President), Michael B. Hortaleza(MOHS Chairman and CEO), Jocelyn M. Aberin(Remed VP-Operations)

Remed owns established brands covering products in four different pharmaceutical categories—Vitacare, Respicare, Pediacare, and Gastrocare with over 20 brands in its portfolio. These products are distributed through some 4,500 outlets in major national and regional drugstores and pharmacy chains.  Remed has grown toa  leadership position in some of the pharmaceutical categories it is present in, and it is poised to introduce 5 more brands in the coming months.

This acquisition follows MOHS’s purchase in early 2024 of a controlling stake in Zenfro Corporation, a distribution company with a strong and expanding network in the South Greater Manila Area handling top food, beverage, home, and personal care products.

The acquisitions are in line with MOHS’s 5-year roadmap to grow into one of the major fully integrated health and wellness companies in the Philippines.

MOHS got a jump start in business by being among the first to bring in affordable test kits and equipment at the start of the COVID-19 pandemic. With the decline of the COVID business, MOHS quickly pivoted to affordable point-of-care and home test kits for the early detection of diseases such as urinary tract infection, dengue, and malaria. From this platform of and experience with affordable healthcare products, MOHS has diversified into other areas of healthcare, including healthcare software and technologies, and point-of-care innovative systems.

MOHS

Signing from Left to Right: Dr. Kenji M. Asano, Jr.(MOHS SVP & Group CFO), Remedios A. Rivera, (Remed Chairman and President), Michael B. Hortaleza(MOHS Chairman and CEO)

“Vertical integration of our health care business allows MOHS to control costs better to make our products more affordable and our business more sustainable,” says Michael B. Hortaleza, MOHS’s Chairman and CEO. “Our acquisitions this year follow our strategy of engaging in businesses that add value to Philippine society, by making a wide range of affordable healthcare products accessible to Filipinos nationwide. This is in line with the Philippine Government’s thrust of Universal Health Care and emphasis on primary and preventative health care.”

MOHS

“Remed’s strategic partnership with MOHS will enable synergies as the strengths of both companies complement each other,” says Remedios A. Rivera, Remed Chairman and President. “Remed can tap MOHS’s distribution expertise in channels it is not currently accessing, while MOHS can tap Remed’s field marketing force to push its health and wellness products to medical professionals. Such a strong partnership will unlock significant local and global growth for Remed.”

“The entry of MOHS into pharmaceuticals through Remed creates synergies from a strategic and financial viewpoint. With our professional operations and automated systems, we can fully realize these synergies,” says MOHS SVP and Group CFO Dr. Kenji M. Asano, Jr.

For more information on Remed Pharmaceuticals, Inc.,  you can visit their website at  https://remedpharmaph.com/.

inventory_backdrop

Companies shift focus as Covid-19 threat diminishes

BY AARON RECUENCO

Mar 3, 2024 05:02 PM

As the threat of Covid-19 has already been significantly reduced in the country, some companies which earlier invested in point-of-care and home test kits, have started shifting its operations to other business lines.

In the case of the local company MOHS, it pivoted its business ventures to businesses include products and services in retail, dermatology and medical services, technology services, distribution and logistics.  

“We knew as early as 2022 that we needed to pivot to non-COVID products with the pandemic winding down. We aggressively moved into new lines, particularly health care and dermatology, as we know these businesses well, and sought the vertical integration of our operations through strategic acquisitions in distribution and logistics and technology services,” said MOHS chief executive officer Michael B. Hortaleza.

“These new businesses remain true to MOHS’s DNA of engaging in businesses that add value to Philippine society. Our COVID diagnostics and consumables business and home-based test kits certainly helped ease the physiological and financial burden that the pandemic brought to many patients,” he added.

While the COVID-19 business amounted for 100 percent of sales in 2021 and 2022, non-COVID sales accounted for 40 percent of MOHS business in 2023 and is projected to increase to 99 percent in 2024.

In 2023, even with COVID-19 cases rapidly declining, MOHS’s revenues grew by 24 percent. 

The group’s chief finance officer, Kenji M. Asano Jr., says, “MOHS’s timely pivot beyond its COVID-19 business, under the strategic direction of CEO Hortaleza, positions MOHS for rapid and sustained growth in 2024 and beyond. MOHS’s new product and services mix is poised to meet the exciting challenges of the post-pandemic era.”   

Diversifying into other business lines with established brands and aggressive competitors meant that the playing field was going to be tougher and in the case of the MOHS, some of its business ventures include dermatology clinics—the Arkana neurocosmetics and Swiss Image skin care products, and Scatter scalp micropigmentation technology for hair loss and bald spots.

Its recent acquisition of Zenfro Corporation, a distribution company in South GMA and modern trade distributing food, beverage and personal care products, expands MOHS’s distribution footprint and product lines.

Likewise, its purchase of Revery Digital Technologies brings it in-house technology services as well as new services in digital transformation and Artificial Intelligence to small and medium-sized enterprises.

MIke Hortaleza, Mohs Diagnostics, MOHS,

MOHS Analytics expands its range of diagnostic home test kits

BusinessMirror November 22, 2023, 2-minute read

HOME test kits proved their value during the height of the Covid-19 pandemic as there came a point when hospitals were turning away patients who needed to be tested and treated. The ability to get tested for Covid in the comfort, privacy and safety of the home helped symptomatics know their Covid status sooner, with accuracy similar to a rapid antigen test in a laboratory. A negative test ensured peace of mind; a positive test meant that necessary treatment can be done earlier.

MOHS Analytics was one of the first to introduce rapid antigen tests for Covid in the Philippines. With the growing acceptance of home test kits as an essential tool for healthcare, MOHS Analytics set up an arm, MOHS Diagnostics MD to expand its line of globally accepted home test kits to include malaria, urinary tract infection, and dengue. Under development is a test for leptospirosis.

MOHS Diagnostics has also introduced an ovulation test kit, which while not detecting disease, will also be a helpful tool for women who want to get pregnant.

“MOHS has grown quickly by addressing market gaps and meeting consumer demand through highly innovative products,” says Chief Innovation Officer Don Paolo San. “Being attuned to the market helps us to deliver what is needed with game-changing technologies.”

Timely detection of disease is crucial for effective health management and preventing the spread of disease. Diseases such as malaria, dengue, and leptospirosis can be fatal if not properly treated as soon as possible. MOHS Diagnostics Home Test Kits allow early identification of potential health concerns, enabling prompt action and care.

But home test kits can only be effective if they are available, accessible, and affordable when needed.

MOHS diagnostic test kits are available without prescription and at affordable prices at over 2,500 retail outlets nationwide, from giant national pharmaceutical chains to smaller regional chains.

“There is a growing realization that disease detection can be quickly and accurately done at home such that the sick can start early treatment and prevent the spread of disease. We are making accurate and affordable self-tests accessible to the Filipinos and this is our contribution to the improvement of the healthcare system in the Philippines,” says MOHS CEO Mike Hortaleza.

At the first symptom of illness, home test kits will provide the sick with essential health insights, without the need for travel or clinic visits. These empower the sick and their caregivers to make informed decisions about their well-being and to seek professional help as warranted.

For more information on MOHS Diagnostics Home Test Kits and to purchase, visit our website at MOHS Diagnostic website https://mohsonline.com.ph/ or MOHS FB https://www.facebook.com/MohsDiagnostics

https://businessmirror.com.ph/2023/11/22/mohs-analytics-expands-its-range-of-diagnostic-home-test-kits/?fbclid=IwAR0503HWh65D3p85BV019qWpAbl-aHsEpVYL5d6Rx7_Z_uuVTGx0wwfPNeM

MOHS

MOHS Analytics expands health and wellness offerings

(The Philippine Star) – November 12, 2023 – 12:00am

MANILA, Philippines — MOHS Analytics, a fast-growing company that provides quality health and wellness solutions through technology, is expanding its line of test kits for various diseases, with over 2,500 drugstores all over the country already offering its affordable kits to test for COVID-19, urinary tract infection, dengue, and malaria.

The company broke into the health industry at the height of the COVID-19 pandemic. It was one of the first to introduce rapid antigen tests to the Philippine market, making home testing as close as the nearest drugstore.

MOHS Diagnostics has also introduced an ovulation test kit, which will be a helpful tool for women who want to get pregnant. Under development is a test for leptospirosis.

“In the first semester of 2023, MOHS Analytics revenues increased by 37 percent compared to the first semester of 2022 while gross profit grew by 30 percent.  Net profit after tax recorded an even greater increase by growing by 35 percent for the same period,” said MOHS CFO Dr. Kenji Asano Jr.

“Our financial results show that Filipinos have accepted home test kits as an important tool in managing their health,” added MOHS CEO Mike Hortaleza. “There is a growing realization that disease detection can be quickly and accurately done at home such that the sick can start early treatment and prevent the spread of disease.”

https://www.philstar.com/business/2023/11/12/2310693/mohs-analytics-expands-health-wellness-offerings/amp